Doximity, Inc. NYSE: DOCS The “LinkedIn for Doctors” After the Crash
The Setup: A Quality Compounder That Just Got Cut in Half
There is a US company that almost nobody in Germany has heard of, but which is enormous among American doctors. The simplest way to describe it is as the “LinkedIn for physicians” – a professional social network where doctors exchange knowledge, communicate with patients by phone and video, read the latest clinical research, and find new jobs. For a long time the thesis was easy to love: revenue was compounding at well over 60%, EBITDA margins were north of 40%, the balance sheet was stuffed with net cash, and the only thing wrong with the stock was that it was breathtakingly expensive.
That was then. This is now – and the change is precisely why this name is worth a fresh, honest look. Doximity reported its fiscal fourth-quarter and full-year 2026 results on 13 May, and the market did not like what it saw. The shares fell roughly 12% on the day, then gapped down another ~24% the next morning, and are now down close to 47% year-to-date, trading around $19–20 versus a 52-week high of $76.51. The hyper-growth darling has, at least for now, become something the tape treats as a disappointment.
So this is not a victory lap. It is the kind of analysis I find far more useful: a before-and-after. The old numbers – 66% revenue growth, a PE above 90 – are now stale. The real Doximity grew revenue 13% in FY2026 and is guiding for 3–5% growth in FY2027 – management literally called it an “AI investment year.” The valuation, meanwhile, has collapsed from absurd to, frankly, interesting.
The investment case in one paragraph: Doximity remains a genuinely world-class business – ~80% of US doctors on the platform, a near-monopoly position at the intersection of healthcare, social media and the cloud, ~55% EBITDA margins, net cash, and prodigious free cash flow ($317.5m in FY26). What broke was not the moat; it was the growth narrative. The pharma HCP ad market has gone soft, and the company is choosing to spend heavily on AI before that spend pays back. My Fair PE model puts the justified multiple at 29x. Against a beaten-down price and a still-growing earnings base, that implies roughly 30% annualized upside over the next three years – if, and only if, you believe the AI investment converts into renewed growth. I do. But I size it as a watchlist-to-small position, not a hero trade.
1. Product, Business Model, Brand & Moat
What the company actually does
Most people know LinkedIn. Doximity is the same idea, but pointed squarely at the medical profession and the broader healthcare industry – a sector that in the US is gigantic, extremely well-funded, and where salaries (and marketing budgets) are very high. Doctors use it to network with colleagues, stay current on clinical publications, look for jobs, manage on-call schedules, handle the digital paperwork that modern medicine drowns in, and – importantly – communicate with patients.
That patient-communication piece is cleverer than it sounds. Through Doximity’s telehealth tools, a physician can call or video a patient from home, while the patient sees the hospital’s number on their caller ID and simply picks up. The doctor gets flexibility; the patient gets a familiar, trusted point of contact. It removes friction on both sides – exactly the kind of “boring but essential” workflow problem I like to see a software business own. As a European, and as someone who is not a physician, I cannot help thinking how badly a tool like this is needed here too – the digital-signature paperwork, the regulatory box-ticking, the fragmented communication – and I can easily imagine the model travelling well beyond the US in time.
How they make money
Today the bulk of revenue still comes from pharmaceutical and hospital advertising, and the logic behind it is the heart of the business. In the old world, a pharma company hired armies of expensive sales reps to visit doctors. Now it can run highly targeted advertising to physicians – down to individual specialties – on Doximity. And since doctors ultimately decide which drugs and treatments get prescribed, that is an extraordinarily valuable audience to reach. Management reports marketing solutions with strong, measurable return on investment for clients.
On top of advertising sit the hiring and telehealth segments, plus a growing stack of paid workflow and AI tools for doctors and health systems. This is the optionality: once you own the relationship with essentially every prescriber in the country, you can layer module after module on top – scheduling, documentation, the new clinical-AI assistant, and so on. It is a textbook “toll-booth” platform, and the total addressable market only grows as each new module is added.
Brand & moat
The brand is as strong as moats get in digital health. Around 80% of US physicians are on the platform, and Doximity has effectively become the default professional identity layer for American medicine. That density is the moat: a competitor cannot simply build a better feed, because the value is the doctors who are already there. Network effects in a regulated, trust-sensitive industry are very hard to dislodge. I would put replaceability as low – the realistic risk is not a rival network stealing members, but clients spending less, which is a demand problem rather than a moat problem.
Single most under-appreciated point: Doximity sits at the cross-section of social media, cloud and healthcare – the three most lucrative themes of the last 15 years – and there are remarkably few pure-play companies there.
By the company’s own framing, it has well under 10% of its addressable market, leaving a long runway IF it can convert engagement into spend.
2. The Market
The prize is the US healthcare marketing and workflow budget – enormous in absolute terms. Doximity’s own view is that it holds a low single-digit-to-high-single-digit share, so the theoretical runway is huge. The defensive character of healthcare is also attractive: people get sick in good times and bad, which historically makes the end-market relatively acyclical.
But – and this is the crucial update – the near-term market has turned cyclical in a way the original thesis did not anticipate. On the Q4 call, management explicitly said short-term demand in the HCP digital pharma ad market is soft, visibility is limited, and they expect overall market growth to be modest, “likely at or below 5%.” Elevated policy uncertainty and macro risk are weighing on pharma marketing budgets. So while the structural market is large and defensive, the cyclical reality right now is that when money is tight, marketing spend is one of the first things customers trim.
Political and regulatory intervention is a live, if manageable, factor: US healthcare is perennially subject to policy shifts, and a network built on pharma advertising to physicians always carries some headline risk. I don’t consider it a thesis-breaker, but it belongs on the risk ledger.
3. Culture & Management
This is founder-led, which is exactly my preference. CEO and co-founder Jeff Tangney previously built Epocrates – the digital drug-reference and clinical-information tool that an enormous share of US doctors relied on for years – before founding Doximity. In other words, he has already built one category-defining product for this exact audience and knows the industry intimately. The other co-founders, Nate Gross and Shari Buck, round out a team with deep medical-tech roots. Insider ownership is high (roughly mid-30s percent), aligning management with shareholders.
The strategy reads as genuinely long-term, and the FY2027 plan is the clearest evidence. Rather than protect near-term margins to flatter the optics after a guidance miss, management is deliberately spending into compute costs, its clinical-AI assistant, and brand marketing – an “AI investment year” that compresses EBITDA margins from ~55% toward ~49%. The market hated it. I am more sympathetic: founders who can afford to invest through a soft patch, funded entirely by their own cash flow, usually come out the other side stronger. There has also been a sensible leadership build-out, with a new CFO (Matt Sonefeldt) and a new president (Dr. Steve Zatz); the fresh CFO may partly explain the conservatism of the guide.
One more cultural marker worth noting: this is the kind of strategic, deeply embedded healthcare asset that larger players covet. Amazon has been pushing into the space (its One Medical acquisition being the obvious example), and it is not hard to imagine Doximity eventually attracting strategic interest. I never underwrite a takeout, but I note the optionality.
4. Financials, Margins & Recent Developments
The company today is a high-margin, cash-generative business growing in the low double digits and decelerating toward the market rate.
The quality of these financials is still genuinely rare. A business that grows double digits, throws off a ~49% free-cash-flow-to-EBITDA conversion profile, runs net cash, and posted its first-ever nine-figure FCF quarter ($107m in Q4) is not a broken company – it is a deceleration story dressed up by the market as a disaster.
The Q4 print itself
Q4 revenue $145.4m, +5% YoY – a small beat on the top line.
Q4 adjusted EPS $0.26, versus ~$0.28 expected and $0.36 a year ago – the miss and the YoY decline are what spooked people.
Q4 adjusted EBITDA ~$65.8m, down ~6% YoY – the first visible sign of the AI-spend margin pressure.
Engagement records: 800,000+ active prescribers on workflow tools; nearly half used the clinical AI; prompts per user roughly doubled from January to April.
So the operational story (engagement, AI adoption) is excellent, while the financial story (decelerating revenue, compressing margins, a soft ad market) is the problem. That tension is the entire investment debate in one sentence.
5. Valuation – The Fair PE Model
Regular readers know I anchor on my Fair PE framework rather than DCF gymnastics. The question is simple: what multiple does a business of this quality, growth and durability deserve, and where does that put the share price over a realistic horizon?
For a company with Doximity’s combination of ~80% market penetration, ~55% EBITDA margins, net cash, prodigious free cash flow and a credible (if currently stalled) growth runway, I assign a Fair PE of 29x. That is a premium multiple, and deliberately so – there are only a handful of businesses globally that pair this profitability with this defensibility. It is also materially below the >90x the stock once commanded, which tells you how much excess optimism has now been wrung out.
The mechanics: applying a 29x Fair PE to an earnings base that grows as the AI investment year gives way to renewed monetization produces a fair value comfortably above today’s ~$19–20 share price. Rolled forward over three years, that path implies approximately 30% annualized upside. I want to be precise about the conditionality here, because it matters: that return is not free. It requires the FY2027 investment year to do its job – for AI adoption to translate into pricing power and new revenue, and for the pharma ad market to stop shrinking. If those happen, 29x on a re-accelerating earnings stream is very achievable. If they don’t, the multiple and the earnings both stay subdued.
Worth noting against my own model: the sell-side has slashed targets hard, with a wide spread – from the high-$30s (BofA at $38) down to the high-teens (Baird ~$18, Evercore ~$19). My Fair PE sits more optimistic than the bears and below the surviving bulls, which is roughly where I like to be when a quality name is being thrown out with the bathwater.
6. Risks – Why This Opportunity Exists
A stock does not fall ~47% in a few months without real reasons. The opportunity exists precisely because the bad news is genuine, not imaginary. Being honest about that is the whole point.
Growth deceleration is real, not optical. FY2027 guidance of 3–5% revenue growth converges toward the broader market’s sub-5% growth. The bears’ core fear – that Doximity’s growth rate collapses to the market rate – has partly come true.
Soft pharma ad market. Management itself flagged weak short-term HCP digital-ad demand, limited visibility, and macro/policy uncertainty. Marketing budgets are cyclical, and that cycle is currently against the company.
The AI margin squeeze. Heavy spending on compute, the clinical-AI assistant and brand marketing compresses EBITDA margins from ~55% to ~49% with no guaranteed payback timeline. “Spend now, earn later” only works if “later” arrives.
AI as a double-edged sword. One downgrade argued that budget managers may turn to AI as a cheaper alternative, making it harder for Doximity to gain share – i.e. AI could commoditize parts of the very ad business that funds everything.
Sentiment overhang. More than ten firms downgraded or cut targets within 24 hours of the print. That kind of coordinated sell-side reset tends to cap a stock for several quarters until the numbers prove the bears wrong.
My own circle-of-competence limit: I am a European investor, not a US physician. I cannot perfectly judge clinical-product stickiness from the outside, and I hold that humility as part of the risk.
Net: the price decline is explained by a credible deceleration plus a deliberate margin investment, amplified by sentiment. None of it touches the moat – which is exactly the condition under which mispricings in high-quality names appear.
7. Latest News & Earnings
The defining event is the 13 May 2026 fiscal Q4/FY2026 release and call. Beyond the headline miss, the substance investors should hold onto:
Record free cash flow of $107m in Q4 – the first nine-figure FCF quarter in the company’s history. The cash engine is intact and getting stronger even as the P&L decelerates.
Management framed FY2027 explicitly as an “AI investment year,” prioritizing long-term positioning over short-term margin.
Clinical-AI traction is the genuine bright spot: nearly half of 800,000+ active prescribers used the AI tools last quarter, and an AI search product for pharmaceutical clients launched – though management expects only a modest near-term revenue contribution.
Leadership: new CFO Matt Sonefeldt and new president Dr. Steve Zatz; the CFO transition may explain some of the guidance conservatism.
The Street’s reaction: a near-unanimous wave of price-target cuts (e.g. Needham to $27, BofA to $38, Baird ~$18) and several outright downgrades.
8. Conclusion & Investment Case
Let me bring it back to where I started. The original story – a 66%-growth, sky-high-multiple compounder – is dead, and anyone still telling it is reading old notes. The new story is more interesting to me precisely because it is harder: a world-class, founder-led, cash-gushing healthcare network, dominant in its niche, deliberately investing through a soft patch, now trading at a fraction of its former price.
My Fair PE of 29x and the implied ~30% annualized three-year upside rest on one belief: that this is a temporary deceleration inside a structurally great business, not the start of permanent decline. The catalysts that would prove me right and force a re-rating are concrete:
AI adoption converting into monetization – turning those doubling prompt volumes and the new pharma AI-search product into real, priced revenue.
A recovery in pharma marketing budgets as policy and macro uncertainty ease, re-accelerating the core ad business above the sub-5% market rate.
Margin recovery once the AI investment year is behind them, with EBITDA margins normalizing back toward the mid-50s.
Continued engagement records demonstrating the platform is becoming more, not less, essential to US physicians.
Optionality from strategic interest, given how coveted a deeply embedded healthcare asset like this is.
How I’m playing it: this is a high-quality watchlist-to-small-position name, not a table-pounding all-in. The quality – high margins, net cash, dominant network – means the downside is cushioned; very little catastrophic can happen to a debt-free business throwing off this much cash. But the near-term growth and sentiment overhang argue against an oversized position today. I own it (directly and through the fund), I’m comfortable adding patiently on weakness, and I’d rather be early and small in a great business than late and large in a cheap one. As always with my picks, you can also gain exposure indirectly through my fund.
Risk Disclaimer & Disclosure
This article reflects my personal opinion and is intended for information and educational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security. Investing in equities carries substantial risk, including the total loss of capital; past performance and forward-looking estimates are no guarantee of future results, and the assumptions in any valuation model (including the Fair PE framework used here) may prove incorrect. Always conduct your own research and consult a qualified, independent financial adviser before making any investment decision.
Conflict of interest: I am invested in Doximity (NYSE: DOCS), both directly and indirectly. Doximity is a holding in the cost-efficient Haas Invest4 Innovation investment fund (invest4.net), which I manage. A potential conflict of interest therefore exists. I have aimed to present the facts – including the negative ones – as objectively as possible, but readers should weigh this disclosure accordingly.